Norstella
Citeline Podcasts
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
Vizitează neapărat site-ul podcastului și susține-i creatorul: www.citeline.com
Autor
Norstella
Categorie
Site-ul podcastului
Cel mai nou episod
19 nov. 2026
Unde asculți?
Podcasturi în aplicație Replaio Radio În curândPodcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor
Episoade
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Apr. 27, 2026 27.04.2026 16:44
本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年4月24日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 伊朗港口封锁对全球制药业的影响;拜耳坚守欧洲市场但寻求更多发展;凯莱拉(Kailera)的重大IPO;2025年最畅销药物;Anthropic聘请诺华CEO。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must...
Scrip's Five Must-Know Things - Apr. 27, 2026 27.04.2026 15:37
Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 24, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO. Story links: https://insights.citeline.com/s...
PD-(L)1/VEGF双抗赛道——中国可否率先改写一线肺癌标准治疗?(Chinese-language podcast) 24.04.2026 12:22
本期《中国生物技术播客》聚焦康方生物的依沃西单抗将如何改写历史,以及在PD-(L)1/VEGF双抗之间是否即将发生国内头对头三期临床试验。 Could PD-(L)1/VEGF Agents Face Off First In China Phase III Trials?
Redefine Modern Biotech Through Smarter Boards, Stronger ROI, and China's Rise 23.04.2026 38:22
As biotech models evolve, boards, clinical leaders, and investors are being forced to rethink how value is created. In this episode, Claire Riches, VP, Clinical Solutions, Citeline is joined by Ross Pettit, Chief Development Officer, Kestrel Therapeutics, to explore how leaner operating models, sharper board governance, ROI‑driven clinical decisions, and the rapid rise of China’s biotech ecosystem...
Scrip M&A Podcast with Cooley Attorneys Kevin Cooper and Bill Roegge. 22.04.2026 38:59
Scrip Senior Writer Joseph Haas interviewed attorneys Kevin Cooper and Bill Roegge of Cooley LLP about recent events and trends in biopharmaceutical merger-and-acquisition activity. They discussed the current state of M&A after a busy conclusion to the first quarter and how that interplays with financing and partnering activity. In addition, Kevin offered tips for smaller companies to get good out...
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Apr. 21, 2026 21.04.2026 18:10
本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年4月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Icotyde或将成为强生史上最重磅产品;daraxonrasib数据助力Revolution;Travere的Filspari成为首个用于治疗FSGS的药物;GSK重金押注B7-H4抗体药物偶联物;以及礼来夺得全球制药销售额榜首。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-mu...
Scrip's Five Must-Know Things - Apr. 21, 2026 21.04.2026 16:52
Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 17, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Icotyde could be J&J’s biggest ever product; daraxonrasib data boost Revolution; Travere’s Filspari becomes first drug for FSGS; GSK bets big on B7-H4 antibody-drug conjugate; and Lilly grabs t...
The Generics Bulletin Podcast: Green Regulations With Medicines for Europe’s Adrian van den Hoven 20.04.2026 22:42
Generics Bulletin senior reporter Urtė Fultinavičiūtė speaks to Medicines for Europe’s director general Adrian van den Hoven about pertinent environmental regulation changes in the region.
Drug Fix: CBER Director Candidate Emerges, US FDA Promotes Leucovorin Pathway 17.04.2026 28:28
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs discuss potential takeaways from the Trump Administration floating ophthalmologist, entrepreneur and Fox News contributor Houman David Hemmati as the next potential Center for Biologics Evaluation and Research director (:34), as well as the appointment of US Food a...
성숙기 진입 중인 ADC 시장…삼성바이오에피스, 차별화 전략 강화 (Korean-language podcast) Apr. 17, 2026 17.04.2026 3:39
김윤철 삼성바이오에피스 상무는 Scrip과의 인터뷰에서 ADC 및 기타 신약개발 전략 등에 대해 이야기했습니다. 이 기사를 요약한 내용입니다. (AI 기반 텍스트 음성 변환 및 음성 모방 도구의 도움을 받아 제작되었습니다) Story link: https://insights.citeline.com/scrip/focus-on-asia/south-korea/samsung-bioepis-sharpens-differentiation-strategy-as-global-adc-market-matures-T4E7D2U4DZFJFIERGRWM7PECTM/
Japan Q1 Roundup: Key Commercial and Policy/Regulatory Developments 17.04.2026 10:19
Join Scrip and The Pink Sheet's Tokyo-based team Lisa Takagi and Ian Haydock for a roundup of key commercial and policy/regulatory developments in Japan's biopharma market over the first few months of this year, including some important corporate divestments and new product approvals. Also a look at how the Iran war is impacting the healthcare sector in the country.
Lilly TuneLab: Breaking Data Silos in Biotech with Federated Learning 13.04.2026 27:38
How can small biotechs tap billion‑dollar AI models without giving up their data? David Wild talks with Eli Lilly's Aliza Apple about Lilly TuneLab, a federated learning platform that lets companies use Lilly’s in-house drug discovery models while keeping their IP and datasets fully private. They dive into early use cases in ADMET and antibody developability, what early-stage users actually do in...
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Apr. 10, 2026 13.04.2026 17:30
本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年4月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 特朗普政府对部分药品及原料药征收100%关税;美国关税政策给获美批准的中国药品带来阴影; 吉利德收购Tubulis;深入解析Neurocrine对Soleno的收购要约;以及对第一季度并购活动的分析。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-k...
Scrip's Five Must-Know Things - Apr. 13, 2026 13.04.2026 16:22
Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Trump’s 100% tariffs and pharma; US tariffs loom over US-approved Chinese drugs; Gilead’s Tubulis buy-out; a closer look at Neurocrine’s Soleno bid; and an analysis of Q1 M&A. Story links: http...
Drug Fix: Leucovorin’s Resurrection, PhRMA’s Leadership Change 10.04.2026 33:45
Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman and Editor-in-Chief Nielsen Hobbs discuss the details of the US Food and Drug Administration’s labeling update for leucovorin (:41), including GSK’s subsequent move to re-withdraw the application (19:45). They also grade the tenure of Steve Ubl as he prepares to leave as Pharmaceutical Research and Manufacturers of Amer...
No Matter What: How Israel Is Positioning Itself as a Global Pharma Innovation Hub 08.04.2026 23:10
Israel has been a prolific source of biotech and AI-driven startups for years, but can it compete as a strategic R&D partner for global pharma? Mati Gill, CEO of AION Labs, makes the case that it can. AION's venture studio model brings together AstraZeneca, Merck KGaA, Pfizer and Teva under one roof to co-create AI-native drug discovery companies, and its portfolio is already producing results: Co...
Inside Step Pharma’s Pan‑Cancer Ambition 07.04.2026 28:53
Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme. #clinicalstrategy #oncology
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Apr. 6, 2026 06.04.2026 18:39
本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年4月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来收购Centessa的意义;Apellis为Biogen注入新能力;中国企业在肥胖症领域取得的快速进展;口服药物在肥胖症治疗中占据主导地位;以及全球制药研发管线规模的缩减。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-l...
Scrip's Five Must-Know Things - Apr. 6, 2026 06.04.2026 17:45
Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline. Sto...
China Biopharma English-Language Podcast: China’s Regulatory Changes In Cell Therapy 03.04.2026 7:26
In this episode of the China biopharma English-language podcast, Xu Hu talks about recently China releasing two guidelines related to CAR-T therapies within a month and the strategic position that the country puts its cell therapy sector. The Pink Sheet stories related to this episode: CAR-T Guidelines Signal China’s Next Phase Of Cell Therapy Regulatory System Building CAR-Ts Win Big In New China...
Five-Minute Podcast: “UK Needs To Align More With The EU” 30.03.2026 4:35
A legal firm’s perspective on how the UK should evolve its medtech regulatory system, global harmonization and opportunities to embed best practice AI.
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Mar. 30, 2026 30.03.2026 16:46
本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年3月27当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 默克公司力推Terns及其他交易;勃林格殷格翰对欧洲创新环境不佳的警示;科伦与默克的协议如何改变了中国的交易格局;神经科学研发重振旗鼓;以及美国新的低密度脂蛋白胆固醇(LDL-C)指南与药物成本。
Why Longevity Is The Next Big OTC Opportunity, With Euromonitor’s Magda Starula 30.03.2026 25:14
In this episode of HBW Insight’s Over the Counter, we’re digging into one of the most talked‑about themes in consumer health right now: longevity. We’re joined by Magda Starula, Health and Beauty Research Analyst at Euromonitor International, to unpack what “healthy longevity” really means, and why it’s quickly moving from niche concept to mainstream commercial opportunity for OTC. We explore how...
Scrip's Five Must-Know Things - Mar.30, 2026 30.03.2026 16:46
Audio roundup of selected biopharma industry content from Scrip over the business week ended Mar.27, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Merck’s case for Terns and more deals; Boehringer’s warning on innovation-unfriendly Europe; how Kelun-Merck pact changed China deal-making; Story Link : https://insights.citeline.com/scrip/podc...
Drug Fix: US FDA Commissioner Martin Makary Completes First Year In Charge 27.03.2026 27:19
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider US Food and Drug Administration Commissioner Martin Makary’s first year in office, including the issues that shaped his tenure (:32), his biggest policy accomplishments (14:12), issues that could emerge in his second year (19:35), and when Makary’s term could end (22:52). #pharma #busin...
Podcasturi asemănătoare
Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice